Comparative Pharmacology
Head-to-head clinical analysis: SEGLUROMET versus STEGLUJAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEGLUROMET versus STEGLUJAN.
SEGLUROMET vs STEGLUJAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEGLUROMET is a fixed-dose combination of ertugliflozin and metformin. Ertugliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Metformin decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.
STEGLUJAN is a combination of ertugliflozin and sitagliptin. Ertugliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1 and GIP), enhancing insulin secretion and reducing glucagon secretion.
Initial: 2.5 mg ertugliflozin/1000 mg metformin twice daily. Titrate based on efficacy and tolerability. Maximum: 5 mg ertugliflozin/2000 mg metformin twice daily.
Initial: 5 mg/100 mg orally once daily; increase dose based on glycemic response up to 15 mg/100 mg.
None Documented
None Documented
Ertugliflozin: terminal half-life ~16.6 hours (range 10-20 h), supporting once daily dosing. Metformin: terminal half-life ~6.2 hours (range 4-8.7 h) in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is 12–15 hours (mean 13.5 h) in patients with normal renal function; approximately 1.5- to 2-fold longer in moderate renal impairment (eGFR 30–59 mL/min) and up to 3-fold longer in severe renal impairment (eGFR <30 mL/min), necessitating dose reduction.
Segluromet (ertugliflozin and metformin) is primarily excreted via renal (ertugliflozin: ~40.9% unchanged in urine; metformin: ~90% unchanged in urine) and fecal/biliary routes (ertugliflozin: ~50.2% in feces as parent and metabolites; metformin: <1% in bile).
Approximately 70% of an absorbed dose is excreted in the urine (30% as unchanged steglujan, 40% as its active glucuronide metabolite), and 30% is excreted in the feces (primarily as metabolites and unchanged drug via biliary secretion).
Category C
Category C
SGLT2 Inhibitor/Biguanide Combination
SGLT2 Inhibitor